ALK and non-small cell lung carcinoma: Based on these findings, various therapeutic strategies have been developed for NSCLC treatment, such as combination cisplatin-based chemotherapy with the anti-angiogenic bevacizumab 10, 11, the use of tyrosine kinase inhibitors to treat EGFR-mutated, ALK or ROS1-rearranged NSCLC patients 12-15.